Over 150 Total Lots Up For Auction at Three Locations - WI 05/27, NV 05/29, CA 06/06

Cecilia Danckwardt-Lillieström

C-RAD appoints new CFO
August 28, 2018
Rad Oncology Radiation Therapy
C-RAD today announces that Cecilia Danckwardt-Lillieström has been appointed Chief Financial Officer effective October 15, 2018, succeeding Therése Björklund who will assume another position within the finance department at the company.

Cecilia has an extensive experience and has held several leading positions within finance. She is currently a Senior Manager & Head of the Uppsala office for the financial audit and consulting firm KPMG, a position she has held for 3 years. Prior to that, she held the position as CFO for Fastum UBC Förvaltning AB. She has also worked for RaySearch Laboratories AB as CFO, as Director of Finance for MySQL AB, for Biotage AB (publ) as Group controller and for PwC as Senior Manager. Cecilia holds a master’s degree in business and Economics from the Uppsala University.

Therése decided to step down from the position as CFO for personal reasons.
stats
DOTmed text ad

We repair MRI Coils, RF amplifiers, Gradient Amplifiers and Injectors.

MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013

stats
“Cecilia´s very broad financial experience will be a great asset for C-RAD supporting the growing organization. I am very much looking forward to work with Cecilia as our CFO and I am confident that she will be a strong addition to the management team of C-RAD.” says Tim Thurn, CEO C-RAD AB

“I am really looking forward to join the management team of C-RAD. I will certainly do my best to contribute in the continuing development of the finance strategy as well as the future growth of C-RAD”, says Cecilia Danckwardt-Lillieström.

“I want to take the opportunity to thank Therése for the excellent work and the support during the past two years. As a member of the management team she has made an important contribution to build up the organization and finance department in a period a significant growth. I very much welcome her decision to stay in the organization after her change.” says Tim Thurn, CEO C-RAD AB.


About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.

You Must Be Logged In To Post A Comment

 

classifieds

Rad Oncology Homepage

UT Southwestern starts construction on $177 million radiation oncology facility in Texas
The 65,000-square-foot facility will include four linear accelerators
FDA expands clearance for P-Cure proton therapy system to full-body and supine treatments
Gantry-less architecture enables installation in vaults originally designed for linear accelerators
TriHealth partners with RevealDx to advance lung nodule assessment using AI
Adds AI-driven decision support to expanding lung cancer program
RaySearch launches RayStation v2025 with expanded auto-planning
Adds support for treatment planning using the Leo Cancer Care upright patient positioning system
GE HealthCare adds AI-driven tools to radiation oncology portfolio
Plans to integrate software from Spectronic Medical into portfolio
P-Cure opens second Israel facility to scale compact proton therapy production
Will handle manufacturing and assembly of the company’s proprietary accelerator technology
Sun Nuclear acquires AI software firm Oncospace to bolster radiation oncology tools
Integrates predictive analytics and cloud-based planning solutions
Penn Medicine to add $224 million proton center, ramp up FLASH research
Will house two ProteusONE proton therapy systems from IBA in a 43,000-square-foot space
Will you be attending this year's National Proton Conference?
Q&A with Jennifer Maggiore, the National Association for Proton Therapy’s (NAPT) executive director
Varian and Embolx to jointly market embolization microcatheter in US
Expanding interventional oncology portfolio with a focus on liver-directed therapies